Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 12/20 | 0.45 |
| ▸ | CHKA | P35790 | 1/20 | 0.36 |
| ▸ | CBLB | Q13191 | 1/20 | 0.34 |
| ▸ | PLK4 | O00444 | 1/20 | 0.34 |
| ▸ | MYLK | Q15746 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22739076 | 0.82 | MAP3K5 (0.40) | MAP3K5CBLBTNF | |
| SCHEMBL935226 | 0.81 | MAP3K5 (0.62) | MAP3K5CHKACBLBPLK4 | |
| SCHEMBL23721029 | 0.80 | MAP3K5 (0.40) | MAP3K5MYLK | |
| SCHEMBL944473 | 0.76 | MAP3K5 (0.62) | MAP3K5CHKACBLB | |
| SCHEMBL944605 | 0.73 | MAP3K5 (0.52) | MAP3K5MYLKTNF | |
| SCHEMBL20473178 | 0.73 | MAP3K5 (0.41) | MAP3K5CHKAMYLKPDE4ATNF | |
| SCHEMBL22738975 | 0.70 | MAP3K5 (0.42) | MAP3K5CBLBMYLKTNF | |
| SCHEMBL944324 | 0.70 | MAP3K5 (0.60) | MAP3K5CBLBMYLK | |
| SCHEMBL934737 | 0.70 | MAP3K5 (0.60) | MAP3K5CBLB | |
| SCHEMBL945424 | 0.70 | MAP3K5 (0.60) | MAP3K5CBLBMYLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3363797-B1 | ORAL DOSAGE FORM OF APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2020-12-02 | — | — | EP | disclosed |